All In Biotech

NDA 015230 · Hikma

Amicar

Aminocaproic Acid · Oral · Antifibrinolytic Agent

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 3, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Jun 4, 1964

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

2 Phase 3, 1 recruiting

FAERS reports

801

606 serious, 144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2024.

INDICATIONS AND USAGE Aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See Warnings . )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 4, 1964 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • AMICAR · AMINOCAPROIC ACID 0.25GM/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Aminocaproic Acid" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemorrhage144
  • off label use67
  • epistaxis61
  • drug ineffective52
  • fall40
  • death37
  • mouth haemorrhage37
  • haemarthrosis36
  • hypotension30
  • contusion29
  • pain29
  • thrombocytopenia27

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20052
200612
20075
20089
200919
201017
201134
201212
201317
201418
201528
201624
201716
201817
201949
202045
202143
202237
202378
2024105
2025113
202698

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 254 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.